CRYO Stock Analysis
CR
Uncovered
American Cryostem Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
American CryoStem Corp. is engaged in the development, market, and licenses patented adipose tissue-based cellular technologies, bio-materials, and related proprietary services. The company is headquartered in Eatontown, New Jersey and currently employs 6 full-time employees. The company went IPO on 2010-10-02. The firm has developed adipose tissue-derived technologies (Adult Stem Cells) for the fields of regenerative and personalized medicine. Its technologies are the basis for the chemistry, manufacturing, and controls (cGMP Manufacturing) of its ATCell autologous cellular therapy product for use in clinical investigations for biologic license applications with the United States Food and Drug Administration (FDA). The firm has developed and refined its pipeline around its cellular product, ATCell, for clinical therapeutic use. The Company’s ATCELL cell lines are cultured in its patented ACSelerate cell culture media. Its CELLECT service is the required platform for the collection and transportation of live adipose tissue samples to its processing facility. Its ACSelerate cell culture media products are manufactured patented cell culture media products for growing human stromal cells. The company also includes ATGRAFT services.